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New cholesterol targets for patients 
at high or very high cardiovascular 
risk and the indications for PCSK9 
inhibitors
To the Editor: Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors are members of a new class of lipid-lowering drugs 
that reduce low-density lipoprotein cholesterol (LDL-C) levels 
on average by 60% when administered alone or when added to 
maximally tolerated statin therapy with or without ezetimibe. There 
is a consistent relationship between lower achieved LDL-C and the 
absolute LDL-C reduction (determined by pretreatment LDL-C 
levels and the LDL-lowering efficacy of the medications), and lower 
risk of cardiovascular events, which is significant within the first 
year of treatment.[1-8] Sub-analysis of an international study has 
demonstrated that the benefit of PCSK9 inhibitors in South African 
(SA) patients with familial hypercholesterolaemia (FH) is comparable 
to that observed in the rest of the world.[9]
In 2018 we published an update of the South African Dyslipidaemia 
Guideline Consensus Statement from the South African Heart 
Association (SA Heart) and the Lipid and Atherosclerosis Society of 
Southern Africa (LASSA) in which we described LDL-C targets and 
recommendations for the use of PCSK9 inhibitors in patients at high 
or very high risk of atherosclerotic cardiovascular disease (ASCVD) 
events.[10] At the time of publication, PCSK9 inhibitors were not 
yet commercially available in SA. SA Heart and LASSA are aligned 
with the European Society of Cardiology (ESC)/European Society 
of Atherosclerosis (EAS), and our recommendations were based on 
those in the 2016 European guidelines.[11]
The ESC/EAS Guideline has recently been updated with lower 
cholesterol targets for patients at high or very high ASCVD risk,[12] 
and these are different from those recommended in the 2018 SA 
guideline.[10] Consequently, we recommend that SA clinicians note 
the revised LDL-C targets and factor these into their therapeutic 
decision-making, as PCSK9 inhibitors are now registered for use in 
SA and available for our patients.
The new recommendations and revised concepts are: [12] 
1.  For patients at very high risk, both for primary prevention and 
secondary prevention, an LDL-C reduction of ≥50% from baseline 
and an LDL-C goal of <1.4 mmol/L are recommended. An LDL-C 
goal of <1.0 mmol/L may be considered for patients who experience a 
second atherosclerotic vascular event within 2 years (not necessarily 
the same type as the first event) while taking maximally tolerated 
statin therapy.
2.  For patients with type 2 diabetes mellitus (T2DM) at very high risk, 
an LDL-C reduction of ≥50% from baseline and an LDL-C goal of 
<1.4 mmol/L are recommended. In patients with T2DM at high risk, 
an LDL-C reduction of ≥50% from baseline and an LDL-C goal of 
<1.8 mmol/L are recommended.
3.  For patients at high risk, an LDL-C reduction of ≥50% from 
baseline and an LDL-C goal of <1.8 mmol/L are recommended.
4.  Targets for patients at moderate and low risk remain <2.6 mmol/L 
and <3.0 mmol/L, respectively.
5.  For patients who present with an acute coronary syndrome (ACS), 
and whose LDL-C levels are not at goal despite already taking a 
maximally tolerated statin dose and ezetimibe, adding a PCSK9 
inhibitor early after the event (if possible during hospitalisation 
for the ACS event) should be considered. If the LDL-C goal is not 
achieved after 4 - 6 weeks in prior lipid-lowering therapy-naive 
patients, despite maximal tolerated statin therapy and ezetimibe, 
addition of a PCSK9 inhibitor is recommended.
6.  For secondary prevention patients at very high risk not achieving 
their goal on a maximum tolerated dose of statin and ezetimibe, a 
combination with a PCSK9 inhibitor is recommended.
7.  In primary prevention for individuals with heterozygous FH at 
very high risk, an LDL-C reduction of ≥50% from baseline and an 
LDL-C goal of <1.4 mmol/L should be considered. Treatment with 
a PCSK9 inhibitor is recommended for very high-risk FH patients 
if the treatment goal is not achieved on maximal tolerated statin 
plus ezetimibe. For very high-risk FH patients (i.e. with ASCVD or 
with another major risk factor) who do not achieve their goals on a 
maximum tolerated dose of statin and ezetimibe, a combination with 
a PCSK9 inhibitor is recommended.
Readers are referred to Table 4 of the 2019 ESC/EAS Guideline[12] for 
criteria defining cardiovascular risk categories. The SA Dyslipidaemia 
Guideline Consensus Statement is available to download (http://
www.samj.org.za/index.php/samj/article/view/12479).
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